Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections (DALARI)

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Staphylococcal Infections

Treatments

Biological: Clindamycin and rifampicin dosages

Study type

Interventional

Funder types

Other

Identifiers

NCT02782078

P140318 / AOR14027

Details and patient eligibility

About

Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA guidelines) but some interaction is observed. The objective of this study is to evaluate and quantify rifampicin interaction on clindamycin

Full description

It could suggest modification of recommended doses or incitement to antibiotic dosage. Thus, theses antibiotics, if association is allowed, could limit fluoroquinolones prescription and avoid some antibiotic resistance.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients ≥18 years of age
osteoarticular infection
staphylococcus detected in bacteriological sampling
sensibility to rifampicin, erythromycin and clindamycin
active intravenous antibiotherapy against staphylococcus detected in bacteriological sampling

Exclusion criteria

septic shock or severe initial sepsis
osteoarticular infection with other microorganism than staphylococcus
contraindication to clindamycin or rifampicin including case of hypersensibility to one of these two antibiotics
pre-existing renal insufficiency or severe renal insufficiency (creatinine clearance <30 ml/min)
serious cognitive disorders
patient under guardianship, trusteeship or non affiliated to social security or CMU (beneficiary or assignee)
refusal to take part in the study and to sign the consent form
pregnancy
lactation
administration of clindamycin or rifampicin within the month before inclusion
treatment with enzymatic inductor or inhibitor within the month before inclusion
participation to another study modifying antibiotic treatment administration